Dr Reddy’s Laboratories on Wednesday said its consolidated net profit increased nearly 2 percent year-on-year to Rs 1,418 crore during the June quarter. The Hyderabad-based drug firm had reported a net profit of Rs 1,392 crore during the April-June period of the previous fiscal year.
Revenue increased 11.4 percent to Rs 8,545 crore for the period under review as against Rs 7,672.7 crore in the year-ago period, Dr Reddy’s Laboratories said in a regulatory filing.
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew 5 percent to Rs 2,278 crore in the first quarter of June 2025. The same was reported at Rs 2,160 Cr in the same period a year ago. The margin was reported at 26.7 percent against 28.2 percent year-on-year (YoY).
The drug firm said its North American sales reduced 11 percent on-year to Rs 3,410 crore as compared with Rs 3,846 crore.
The company also collaborated with Alvotech for codevelopment, manufacture & commercialization of pembrolizumab, it said in a release.
Shares of Dr Reddy’s Laboratories settled higher at Rs 1,248 per share on the NSE, up 0.65 percent.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
